Citi Pharma Limited has entered into an agreement with Murli Krishna Pharma Private Ltd, a company incorporated and existing under the relevant laws of India.  The pharma company shared this development with the Pakistan Stock Exchange and added that the  exclusive strategic partnership will provide  high-quality Active Pharmaceutical Ingredients  to Citi Pharma Limited in the Pakistan market.    Murli Krishna Pharma Private Ltd is committed to supplying the Exclusive Products to Citi Pharma Limited in accordance with the highest quality standards in the pharmaceutical industry, complying with British Pharmacopoeia (BP) or United States Pharmacopeia (USP) standards, or as specified by our regulatory team.         This agreement is anticipated to generate a turnover increase of 2.8 billion, with the cost of sales expected to rise by 2.38 billion. The increase in operational costs due to this agreement is projected to be minimal, as we will be leveraging Citi Pharma’s existing resources.      Upon the successful completion of Phase-1 of this agreement (the first two years), Citi Pharma Limited and Murli Krishna Pharma Private Ltd have agreed to discuss and negotiate the expansion of our supply chain to other countries, including but not limited to the USA and the Kingdom of Saudi Arabia. (ICE ISLAMABAD)

Fonte notizia: profit